171 Oyster Point Blvd, Suite 200
South San Francisco
About Maze Therapeutics
Maze Therapeutics is translating novel genetic insights into lifesaving medicines, through an approach that integrates human genetics and functional genomics. Advances in these areas have enabled us to decode the mysteries of genetic modifiers in a range of severe diseases, which we aim to turn into medicines that mimic protective mutations.
What are genetic modifiers?
Despite an understanding of the genetic basis for many diseases, it remains a mystery why some people with a disease-causing mutation never get sick. This is often due to genes elsewhere in our DNA that affect the severity of disease and can provide a natural form of protection.
The Maze approach
Dramatic advances in human genetics and functional genomics now enable us to decode the mysteries of genetic modifiers in a range of severe diseases. Today, we believe we can systematically identify genetic modifiers and turn these insights into medicines. We have assembled a world-class team to realize this vision, including creative scientific pioneers, experienced company builders and biotech industry leaders.
Join us in our pursuit to change lives by translating genetic insights into medicine - view our job postings with the link to the left.
23 articles with Maze Therapeutics
Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced that Sekar Kathiresan, M.D., a Maze co-founder, has joined the company’s board of directors.
The U.S. Food and Drug Administration had a busy week leading up to the Labor Day holiday. Here’s a look at the agency’s recent activities.
Maze Therapeutics Announces FDA Orphan Drug Designation Granted to MZE001 for the Treatment of Pompe Disease
Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to MZE001, the company’s investigational product for the treatment of Pompe disease.
Maze Therapeutics Announces Publication in Nature Describing a Novel Mechanism Linking Well-Established Genetic Drivers of ALS and FTD
Maze Therapeutics, today announced the publication in Nature of new findings describing a connection between genetic variation in UNC13A, a gene critical to the function of the nervous system, and the abnormal build-up of TDP-43, a hallmark molecular characteristic of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
Maze Therapeutics Announces Phase 1 Trial Initiation Evaluating MZE001 as a Potential Oral Treatment for Pompe Disease
Maze Therapeutics today announced the initiation of dosing in the company’s Phase 1 clinical trial of MZE001 in healthy volunteers.
Maze Therapeutics Presents New Preclinical Data Supporting Advancement of MZE001 as a Potential Treatment for Pompe Disease
Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced new preclinical data supporting the advancement of MZE001, which aims to address Pompe disease by reducing pathologic glycogen accumulation through the inhibition of muscle glycogen synthase (GYS1).
Maze Therapeutics to Present Preclinical Data Highlighting MZE001 as a Potential Treatment for Pompe Disease at 2022 WORLD Symposium
Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced the company will present new preclinical data supporting the advancement of MZE001, an oral, selective and potent muscle glycogen synthase (GYS1) inhibitor that aims to address the underlying cause of Pompe disease.
Maze Therapeutics Announces $190 Million Financing to Support the Advancement of Nine Precision Medicine Programs and Compass Platform for Genetically Defined Diseases
Maze Therapeutics today announced a $190 million financing led by Matrix Capital Management.
The company has produced a varied pipeline focused on the development of precision pharmacological treatments for nine different programs.
Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced that Jason Coloma, Ph.D, president and chief executive officer of Maze, will present a company overview at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022, at 1:30 p.m. ET.
3/26/2021Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Maze Therapeutics Reveals Its Initial Three Lead Programs Targeting Underlying Genetic Drivers of Life-Threatening Diseases
Additional Novel Research Programs Advancing via COMPASS in Cardio/Renal, Cardiovascular, Neurology, Ophthalmic and Metabolic Diseases
Maze Therapeutics, a company translating genetic insights into new precision medicines, announced that Atul Dandekar, a successful business leader with nearly 25 years of pharmaceutical industry experience, has joined the Company as chief strategy officer.
Maze Therapeutics and Alloy Therapeutics Form Broadwing Bio to Develop Antibody Therapies for Genetically Validated Targets in Ophthalmic Diseases
Maze Therapeutics, a company focused on translating genetic insights into new medicines, and Alloy Therapeutics, a company developing platforms and services to enable drug discovery, today announced the formation of Broadwing Bio to develop targeted antibody therapies for the treatment of ophthalmic diseases
10/9/2020Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Maze Therapeutics Expands Experienced Management Team with Appointment of Sarah Noonberg, M.D., Ph.D., as Chief Medical Officer
Maze Therapeutics, a company focused on translating genetic insights into new medicines, today announced that Sarah Noonberg, M.D., Ph.D., has been appointed as the company’s chief medical officer. Dr. Noonberg brings significant industry and clinical experience to Maze as the company works to advance its pipeline. “Sarah is an exceptional leader who has helped guide multiple companies through various sta
Check out this article for the impacts that Biotech Bay companies are experiencing due to COVID-19.
BioSpace is proud to present its NextGen Bio “Class of 2020,” a list of up-and-coming life science companies in North America that launched no earlier than mid-2018.
Maze Therapeutics, a company focused on translating genetic insights into new medicines, announced that Jonathan Lim, M.D., founder and managing partner at City Hill Ventures, has joined the company’s board of directors.
Maze Therapeutics Appoints Drug Development Expert Richard Scheller, Ph.D., to its Board of Directors
Dr. Scheller was previously the head of therapeutics and chief scientific officer at 23andMe.